The Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these markets. However, the high cost of therapeutic leukapheresis andc cellular therapies, stringent donor recruitment criteria, and long procedural time for leukapheresis are restraining the growth of this market to a certain extent.
By type, the leukapheresis disposables segment is expected to account for the largest share of the leukapheresis products market
Based on type, the leukapheresis market is segmented into leukapheresis disposables and leukaphersis devices. The large share of the leukapheresis disposables segment can be attributed to the recurrent use of disposables during leukapheresis procedures, increasing adoption of leukapheresis products for the collection of leukopaks and isolated PBMCs from leukopaks for rese
Leukapheresis Market worth $91 million by 2026 - Exclusive Report by MarketsandMarkets Leukapheresis Market by Product (Devices, Filters, Columns, Disposables), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2026 , published by MarketsandMarkets, the global Leukapheresis Market is projected to reach USD 91 million by 2026 from USD 61 million in 2021, at a CAGR of 8.4% during the forecast period. The leukopaks market is expected to reach USD 662 million by 2026, at a CAGR of 41.9%.
Browse in-depth TOC on
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148
The Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these mar
SARS-CoV-2 spike S1 subunit induces hypercoagulability
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), is characterized by a range of clinical presentations. The vascular complications of the condition include a range of various coagulopathies that cause bleeding and thrombocytopenia or a hypercoagulable state. A new preprint research paper posted to the
medRxiv server describes the role of a fibrinogen-related protein in inducing these clinical features of COVID-19.
Cytokine dysregulation
Earlier research has shown a change in circulating cytokines involved in the inflammatory and coagulation pathways, indicating dysregulation of these biomarkers and the endothelium. These include fibrin(ogen), D-dimer, P-selectin and von Willebrand Factor (VWF), C-reactive protein (CRP), and other cytokines that bind to endothelial receptors.
| Press Release
Alphanate: A Sterile, Lyophilized Concentrate of FVIII (AHF) and Von Willebrand Factor - Global Drug Insight and Market Forecast 2017-2030
ResearchAndMarkets.com s offering. Alphanate - Drug Insight and Market Forecast - 2030 report by the publisher outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Alphanate in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product.
The product details cover mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlight